{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:03:06Z","timestamp":1784872986145,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Background<\/jats:title>\n Systemic administration of immunotherapy via intravenous injection is frequently associated with off-target toxicity throughout the body. In contrast, intratumoral injection has emerged as a promising strategy to mitigate systemic adverse effects. However, data regarding the safety of CT-guided intratumoral immunotherapy remain limited.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This pooled prospective cohort study included patients from several single-arm clinical trials. Eligible participants had histologically confirmed advanced solid tumors that were refractory or intolerant to standard therapies. Each participant had at least one measurable tumor lesion accessible for puncture under imaging guidance. All patients received CT-guided intratumoral injection of various ICIs (PD-1, PD-L1, and CTLA-4 inhibitors) either alone or in combination, or of CAR-T cells. The primary endpoint was safety of the treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 169 patients were included in the study cohort, with a median follow-up duration of 8.4 months (range, 1.0\u201338.0 months). Grade 3\u20134 adverse events occurred in 15 patients (8.88%), comprising 10 (5.92%) grade 3 and 5 (2.96%) grade 4 events; no treatment-related deaths were observed. Efficacy outcomes included 4 patients (2.37%) with complete response (CR), 15 (8.88%) with partial response (PR), 142 (84.02%) with stable disease (SD), and 8 (4.73%) with progressive disease (PD). The objective response rate (ORR) was 11.24%, and the disease control rate (DCR) was 95.27%. The median progression-free survival (PFS) was 3.6 months (95% CI, 3.1\u20134.1 months), and the median overall survival (OS) was 8.8 months (95% CI, 8.2\u20139.3 months).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This study indicates the safety and preliminary therapeutic potential of intratumoral injection. Intratumoral injection may be a promising strategy for mitigating systemic toxicity; however, further research is necessary to validate its therapeutic efficacy.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration<\/jats:title>\n \n https:\/\/clinicaltrials.gov<\/jats:ext-link>\n , identifier NCT03198052, NCT03769129, NCT03755739, NCT03952065, and NCT05341492.\n <\/jats:related-object>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1869154","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:35:35Z","timestamp":1784871335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CT-guided intratumoral immunotherapy for advanced solid tumors: a prospective clinical study of safety and systemic antitumor effects"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongqiong","family":"Ou","sequence":"first","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, the First Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binjia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Pathology, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Ul Huda","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzhai","family":"Qin","sequence":"additional","affiliation":[{"name":"Center for Clinical Trial, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingde","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shunde Chinese Medicine Hospital, the Affiliated Hospital of Traditional Chinese Medicine University of Guangzhou","place":["Foshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hainan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology; Translational Medicine Center; Guangzhou Key Laboratory for Research and Development of Nano-Biomedical Technology for Diagnosis and Therapy; Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment; Central Laboratory, the Second Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J Control Release"},{"key":"B2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","article-title":"Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/pharmaceutics16091181","article-title":"Alternative strategies for delivering immunotherapeutics targeting the PD-1\/PD-L1 immune checkpoint in cancer","volume":"16","author":"Hoshi","year":"2024","journal-title":"Pharmaceutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/vaccines13040429","article-title":"Intratumoral immunotherapy in breast cancer","volume":"13","author":"Baumrucker","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.01.072","article-title":"Locoregional drug delivery for cancer therapy: preclinical progress and clinical translation","volume":"367","author":"Shaha","year":"2024","journal-title":"J Control Release"},{"key":"B6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.omto.2021.12.018","article-title":"Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors","volume":"24","author":"Kimura","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115083","article-title":"Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer","volume":"202","author":"Mikhail","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01422-4","article-title":"Intratumoral immunotherapy: is it ready for prime time","volume":"25","author":"Ghosn","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2311","article-title":"Phase I study of adavosertib with radiotherapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy - beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41419-025-07733-7","article-title":"Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma","volume":"16","author":"Pan","year":"2025","journal-title":"Cell Death Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1038\/s41467-024-49034-1","article-title":"Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8(+)T cells for systemic antitumor responses","volume":"15","author":"Zou","year":"2024","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/cells13171478","article-title":"An abscopal effect on lung metastases in canine mammary cancer patients induced by neoadjuvant intratumoral immunotherapy with cowpea mosaic virus nanoparticles and anti-canine PD-1","volume":"13","author":"Sergent","year":"2024","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41467-021-23442-z","article-title":"Intratumoral SIRP\u03b1-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy","volume":"12","author":"Bian","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e002953","DOI":"10.1136\/jitc-2021-002953","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.01.003","article-title":"Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural Malignancies in a phase I\/II clinical trial","volume":"165","author":"Ghosn","year":"2022","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216798","article-title":"Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer","volume":"588","author":"Tang","year":"2024","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217111","article-title":"Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects","volume":"598","author":"Li","year":"2024","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.007","article-title":"Combination with oxaliplatin improves abscopal effect of oncolytic virotherapy through reorganization of intratumoral macrophages","volume":"33","author":"Tomita","year":"2025","journal-title":"Mol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385484","article-title":"Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies","volume":"15","author":"Mantooth","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479483","article-title":"Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","volume":"15","author":"Skalickova","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217464","article-title":"Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models","volume":"612","author":"Uher","year":"2025","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e008872","DOI":"10.1136\/jitc-2024-008872","article-title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"12","author":"Schenker","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1869154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:35:36Z","timestamp":1784871336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1869154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1869154"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1869154","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1869154"}}